BlueSky Immunotherapies GmbH news

BlueSky Immunotherapies has expanded and secured its intellectual property portfolio. The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform.

Corresponding patents were recently granted in (EP 3063273), USA (US 10480013), and China (CN 2019112100112140) covering key markets of the technology. Patent protection will be in force until 2034.

Viennese biotechnology company BlueSky Immunotherapies GmbH (Ltd.) has completed the second cohort of its phase 1 clinical trial against HPV 16.

The results: Intradermal administration has been confirmed to be safe and well tolerated. Preliminary indications of effi

We are glad to announce that scientists from our biotechnology company BlueSky Immunotherapies GmbH (Ltd.) have achieved great success in completely and permanently eliminating equine sarcoids and bovine papillomavirus that causes this aggressive form of skin cancer that horses often suffer from.

By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector platform for the induction of interferon and expression of tumor antigens. delNS vectors have man